HDFC Pharma and Healthcare Fund · Regular · Growth
HDFC Mutual Fund · Managed by Nikhil Mathur
NAV
₹21.5400
as of 28 Sept 2026
Expense Ratio
2.11%
AUM
₹2,282 Cr
Lumpsum returns (CAGR)
- 1Y
- +28.64%
- 3Y
- —
- 5Y
- —
- Since Inception
- +29.32%
SIP returns (XIRR)
- 1Y
- +33.46%
- 3Y
- —
- 5Y
- —
- Since Inception
- +24.72%
Not enough verified history to show honest backtest scenarios (this fund is under 3 years old).
Risk Metrics
Trailing 1 year, annualised1.54
Sharpe Ratio
+0.25
Alpha
0.37
Beta
1.50
Sortino
13.11%
Std Dev
-8.39%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about HDFC Pharma and Healthcare Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Divis Laboratories Ltd.9.54%
- 2Sun Pharmaceutical Industries Ltd.8.94%
- 3Torrent Pharmaceuticals Ltd.4.08%
- 4Max Healthcare Institute Limited4.06%
- 5Lupin Ltd.4.04%
- 6Cipla Ltd.3.94%
- 7Aster Dm Quality Care Limited3.84%
- 8Neuland Laboratories Limited3.70%
- 9Anthem Biosciences Limited3.48%
- 10Acutaas Chemicals Limited3.24%
What this fund does
HDFC Pharma and Healthcare Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
HDFC Pharma and Healthcare Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by HDFC Mutual Fund. The fund has been operational for over 3 years. It manages assets worth ₹2,282 Cr, reflecting investor confidence in the fund's strategy. The fund is managed by Nikhil Mathur. It benchmarks its performance against BSE Healthcare Index TRI. The current expense ratio is 2.11%.